ABBV vs XOM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Exxon Mobil Corporation · Energy
$154.46
-40.5% upside to fair value
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
XOM trades at a lower forward P/E
(23.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
XOM |
| Current Price |
$197.69 |
$154.46 |
| Fair Value Estimate |
$210.22 |
$91.87 |
| Upside to Fair Value |
+6.3%
|
-40.5%
|
| Market Cap |
$349.7B |
$642.0B |
| Forward P/E |
83.3x
|
23.2x
|
| EV / EBITDA |
23.4x
|
10.3x
|
| Price / Sales |
5.7x
|
2.0x
|
| Price / FCF |
18.7x
|
27.2x
|
| Revenue Growth YoY |
+10.0%
|
-1.3%
|
| Gross Margin |
70.2%
|
21.7%
|
| Operating Margin |
26.7%
|
10.5%
|
| Return on Equity |
-361.6%
|
11.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.68%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Exxon Mobil Corporation operates as a global integrated oil and gas company with significant operations in upstream, energy products, chemical products, and specialty products segments. The company benefits from a highly experienced management team with decades of internal tenure, led by CEO Darren Woods. Despite strong cash flow generation and operational scale, Exxon is currently overvalued, tr…
Accumulation Zones
| Metric |
ABBV |
XOM |
| Zone Low |
$157.66 |
$68.90 |
| Zone High |
$178.69 |
$78.09 |
| In Buy Zone? |
No
|
No
|